<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02970929</url>
  </required_header>
  <id_info>
    <org_study_id>SEP361-202</org_study_id>
    <secondary_id>2016-001556-21</secondary_id>
    <nct_id>NCT02970929</nct_id>
  </id_info>
  <brief_title>An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia</brief_title>
  <official_title>A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An extension study of safety and tolerability of SEP-363856 in adult subjects with
      schizophrenia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 26 week, multiregional, open-label extension study designed to evaluate the
      long-term safety and tolerability of SEP-363856 for the treatment of subjects with
      schizophrenia who have completed the 4 week double-blind treatment phase of Study SEP361-201.

      No statistical hypothesis tests will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2017</start_date>
  <completion_date type="Actual">January 29, 2019</completion_date>
  <primary_completion_date type="Actual">January 29, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) leading to discontinuation</measure>
    <time_frame>27 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute values from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (hematology)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361 202 in clinical laboratory tests (hematology)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (serum chemistry)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (serum chemistry)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (urinalysis)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (urinalysis)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (glucose and lipid panel)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361 202 in clinical laboratory tests (glucose and lipid panel)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (prolactin)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (prolactin)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (glycosylated hemoglobin (HbA1c))</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (glycosylated hemoglobin (HbA1c))</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (vital signs)</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (vital signs)</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (body weight)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (body weight)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (BMI)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (BMI)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (blood pressure [supine and standing]).</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (blood pressure [supine and standing]).</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (heart rate [supine and standing])</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (heart rate [supine and standing])</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (12 lead ECGs)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (12 lead ECGs)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of suicidal ideation and suicidal behavior using the C-SSRS</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of suicidal ideation and suicidal behavior using the Columbia - Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to relapse during the 26 week OL period for subjects who demonstrated a clinical response to 4 weeks of treatment with SEP-363856.</measure>
    <time_frame>26 weeks</time_frame>
    <description>Relapse will be defined as the onset of any of the following:
An increase in PANSS total score ≥ 30% from the PANSS total score at clinical response and a CGI S score ≥ 3
Re-hospitalization for worsening of psychosis
Emergence of suicidal ideation, homicidal ideation and/or risk of harm to self or others.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of relapse during the 26 week OL period for subjects who demonstrated a clinical response to 4 weeks of treatment with SEP-363856.</measure>
    <time_frame>26 weeks</time_frame>
    <description>Relapse will be defined as the onset of any of the following:
An increase in PANSS total score ≥ 30% from the PANSS total score at clinical response and a CGI S score ≥ 3
Re-hospitalization for worsening of psychosis
Emergence of suicidal ideation, homicidal ideation and/or risk of harm to self or others.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in Positive and negative syndrome scale (PANSS) total score and subscale scores (positive, negative, and general psychopathology)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in Clinical global impression - severity (CGI-S) score.</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361 202 in Brief Negative Symptom Scale (BNSS) total score.</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in Montgomery-Asberg Depression Rating Scale (MADRS) total score.</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve a response, defined as a 20% or greater improvement in PANSS total score from the baseline</measure>
    <time_frame>26 weeks</time_frame>
    <description>calculated using (1) the DB Baseline of Study SEP361-201 for subjects assigned to double-blind SEP-363856, and (2) the OL Baseline of Study SEP361-202 for subjects assigned to double blind placebo.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>SEP-363856</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEP-363856 capsule (25 mg, 50 mg, or 75 mg) once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEP-363856</intervention_name>
    <description>One SEP-363856 capsule (25 mg, 50 mg or 75 mg (flex)) daily for 26 weeks</description>
    <arm_group_label>SEP-363856</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subject must give written informed consent and privacy authorization prior to participation
        in the study and able to comply with the protocol, in the opinion of the investigator.

          -  Subject has completed Study SEP361 201 through Week 4

          -  Subject has not taken any medication other than the study drug for the purpose of
             controlling schizophrenia symptoms during Study SEP361 201.

          -  Female subject must have a negative urine pregnancy test at Visit 7 of Study SEP361
             201; females who are post-menopausal (defined as at least 12 months of spontaneous
             amenorrhea) and those who have undergone hysterectomy or bilateral oophorectomy will
             be exempted from the pregnancy test.

          -  Male subjects with female partner(s) of childbearing potential must agree to avoid
             fathering a child and use acceptable methods of birth control from screening until at
             least 30 days after the last study drug administration

        Exclusion Criteria:

          -  Subject answers &quot;yes&quot; to &quot;suicidal ideation&quot; Item 4 (active suicidal ideation with
             some intent to act, without specific plan) or Item 5 (active suicidal ideation with
             specific plan and intent) on the C-SSRS assessment at Visit 7 of Study SEP361 201.
             Subjects who answer &quot;yes&quot; to this question must be referred to the Investigator for
             follow up evaluation.

          -  Subject has a clinically significant abnormality including physical examination, vital
             signs, ECG, or laboratory test at Visit 7 of Study SEP361 201 that the investigator in
             consultation with the medical monitor considers to be inappropriate to allow
             participation in the study.

          -  Subject has a positive urine drug screen (UDS) or breath alcohol test at Visit 7 of
             Study SEP361 201.

          -  Subject is pregnant or lactating.

          -  Subject is at high risk of non-compliance in the Investigator's opinion.

          -  Subject is in the opinion of the Investigator, unsuitable in any other way to
             participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CNS Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woodland International research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNRI-Los Angeles, LLC</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>90660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kashinath Yadalam</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70629</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research, LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bugát Pál Kórház-Rendelőintézet, Rehabilitációs Elmegyógyászati Osztály</name>
      <address>
        <city>Gyongyos</city>
        <state>Dózsa György</state>
        <zip>út 20-22</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Pszichiatriai Osztaly</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Universitar de Urgenta Militar Central &quot;Dr. Carol Davila&quot;</name>
      <address>
        <city>Bucuresti</city>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul de Evaluarea si Tratament al Toxicodependentelor pentru Tineri &quot;Sf. Stelian&quot;, Sectia Psihiatrie</name>
      <address>
        <city>Bucuresti</city>
        <zip>060222</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>spitalul Clinic de Neuropsihiatrie Craiova ,Clinica II Psihiatrie</name>
      <address>
        <city>Craiova</city>
        <zip>200473</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul de Psihiatrie Socola Iasi, Sectia Psihiatrie III Acuti</name>
      <address>
        <city>Iasi</city>
        <zip>700282</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sverdlov Regional Psychiatric Clinical Hospital</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Petersburg SHI Psychiatrical hospital #1 n.a. Kaschenko</name>
      <address>
        <city>Gatchina</city>
        <zip>188357</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPHI &quot;City Mental Hospital #3 n.a. I.I.Skvortsov-Stepanov&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI Regional Clinical Psychiatry Hospital of St. Sofia</name>
      <address>
        <city>Saratov</city>
        <zip>410060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBEI HE &quot;Smolensk State Medical University&quot; of the MoH of the RF</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Psychiatric Hospital of St. Nikolay Chudotvorets</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FB=SBI&quot;Saint Petersburg Scientific and Research Psychoneurological Institute n.a. V.M. Bekhterev&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb SBIH &quot;City Psychoneurological Dispensary #7 (with inpatient facilities)&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Psychoneurological Hospital #3, Dept of Crisis Cond &amp; Primary Psych Episode #1</name>
      <address>
        <city>Ivano Frankivsk</city>
        <zip>76014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Kharkiv RCPH#3 Center of Emerg PsychSI Inst of Neur, Psych &amp; Narc of NAMSU, Unit of Emergency Psychiatry and Narcology</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Kharkiv Regional Clinical Psychiatric Hospital #3, Psychiatric Department of Primary Psychotic Episod</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI Kherson Regional Psychiatric Hospital of Kherson RC</name>
      <address>
        <city>Kherson, Vil Stepanivka</city>
        <zip>73488</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TMA Psychiatry in Kyiv Center of NT &amp; Rehabilitation of Psychotic Conditions</name>
      <address>
        <city>Kyiv</city>
        <zip>04080</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI Odesa Regional Medical Center of Mental Health</name>
      <address>
        <city>Odesa</city>
        <zip>65006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI Cherkasy Regional Psychiatric Hospital of ChRC, Femail Dept #11, Male Dept #12</name>
      <address>
        <city>Smila</city>
        <zip>20708</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ternopil RCCPH Depts of Psychiatry #2 (m) &amp; Psychiatry #6 Ternopil I.ya. Gorbachevskyi SMU</name>
      <address>
        <city>Ternopil</city>
        <zip>46020</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Transcarpathian Regional Narcological Dispensary</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI O.I. Yuschenko VRPsH Depts #7 &amp; #10 M.I. Pyrogov VNMU</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>November 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2016</study_first_posted>
  <disposition_first_submitted>December 2, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>December 2, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 3, 2019</disposition_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

